| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6119878 | Journal of Clinical Virology | 2016 | 7 Pages |
Abstract
Despite increasing HBV vaccination completion, provision of financial incentives was not associated with enhanced serological protection. Further research into factors which affect response rates and the optimal vaccination regimen and incentive schemes for this population are needed.
Keywords
HBcAbseroconversionPWIDICERNHMRCHBsAgHBsAbIQRAustralian dollarsIU/mlRandomised controlled trialHepatitis B surface antigenribonucleic acidRNApeople who inject drugsOstImmunisationinter quartile rangeopioid substitution treatmentNational Health and Medical Research Councilconfidence intervalContingency managementfinancial incentivesImmunityincremental cost effectiveness ratiohepatitis B core antibodyHBVHepatitis C virusHCVhuman immunodeficiency virusHIVhepatitis B virus
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Carolyn A. Day, Marian Shanahan, Handan Wand, Libby Topp, Paul S. Haber, Craig Rodgers, Rachel Deacon, Nick Walsh, John Kaldor, Ingrid van Beek, Lisa Maher,